Contrasting NeurAxis (NRXS) and Its Competitors

NeurAxis (NASDAQ:NRXS) is one of 74 publicly-traded companies in the “Electromedical equipment” industry, but how does it weigh in compared to its competitors? We will compare NeurAxis to related businesses based on the strength of its valuation, institutional ownership, analyst recommendations, risk, earnings, profitability and dividends.

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for NeurAxis and its competitors, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NeurAxis	0	0	1	0	3.00
NeurAxis Competitors	234	751	1973	49	2.61

As a group, “Electromedical equipment” companies have a potential upside of 24.61%. Given NeurAxis’ competitors higher possible upside, analysts clearly believe NeurAxis has less favorable growth aspects than its competitors.

Insider and Institutional Ownership

11.8% of NeurAxis shares are owned by institutional investors. Comparatively, 45.7% of shares of all “Electromedical equipment” companies are owned by institutional investors. 13.6% of shares of all “Electromedical equipment” companies are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Profitability

This table compares NeurAxis and its competitors’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
NeurAxis	-594.55%	N/A	-899.27%
NeurAxis Competitors	-188.94%	-39.24%	-3.00%

Valuation & Earnings

This table compares NeurAxis and its competitors top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
NeurAxis	$2.46 million	-$14.63 million	-0.70
NeurAxis Competitors	$1.00 billion	$86.43 million	-6.94

NeurAxis’ competitors have higher revenue and earnings than NeurAxis. NeurAxis is trading at a higher price-to-earnings ratio than its competitors, indicating that it is currently more expensive than other companies in its industry.

Summary

NeurAxis competitors beat NeurAxis on 8 of the 12 factors compared.

About NeurAxis

NeurAxis, Inc., a medical technology company, focuses on developing neuromodulation therapies to address chronic and debilitating conditions in children and adults in the United States. It offers IB-Stim, a percutaneous electrical nerve field stimulation system intended to be used in patients 11-18 years of age with functional abdominal pain associated with irritable bowel syndrome. The company sells its products to healthcare companies, including hospitals and clinics. The company was formerly known as Innovative Health Solutions, Inc. and changed its name to NeurAxis, Inc. in March 2022. The company was founded in 2011 and is headquartered in Carmel, Indiana.